Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming
Company adds experienced clinical development expert to its board of directorsOSLO, Norway (BUSINESS WIRE) Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company's Extraordinary General Meeting.Adrian Senderowicz is a US Board certified medical oncologist, and.
Company adds experienced clinical development expert to its board of directors Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company's Extraordinary
Oncoinvent presents preclinical dosimetry data documenting a therapeutic relevant biodistribution of Radspherin as well as preclinical data on the potential synergistic effects of Radspherin with existing
The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trialsOSLO, Norway (BUSINESS WIRE) Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, tod.